Latest news with #NSCLC
Medscape
2 days ago
- Business
- Medscape
FDA Approves Zongertinib for HER2-Mutated NSCLC
The FDA has granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.) for certain adults with unresectable or metastatic nonsquamous non-small cell lung cancer (NSCLC). Specifically, the TKI was approved for patients whose tumors harbor HER2 ( ERBB2 ) tyrosine kinase domain-activating mutations as detected by an FDA-approved test and who have received prior systemic therapy, according to the approval notice. The novel agent is the first orally administered, targeted therapy for previously treated patients with HER2 ( ERBB2 )-mutant NSCLC, who have poor prognosis and limited treatment options, Boehringer Ingelheim noted in a February 2025 press release announcing the agent having been granted priority review. Zongertinib had previously received breakthrough therapy and fast track designation. The FDA also approved the Oncomine DX Target Test (Life Technologies Corporation) to help detect the target mutations and identify patients who may be eligible for zongertinib treatment. 'With the approval of zongertinib, we have an effective, targeted, orally administered treatment option for patients with HER2 (ERBB2)-mutant non-small cell lung cancer in the U.S. that not only elicits a durable response but, importantly, has a manageable safety profile,' said John Heymach, MD, PhD, chair of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center, Houston, and coordinating investigator for the Beamion-LUNG 1 trial, stated in a press release. 'In a patient population where there are currently limited treatment options, this approval represents a significant advancement in cancer care.' Zongertinib approval was based on efficacy demonstrated in the open-label phase 1b Beamion LUNG-1 dose escalation trial. Among 71 patients who had received prior platinum-based chemotherapy but who had not received a HER2-targeted TKI or antibody-drug conjugate, 75% had an objective response and 58% had duration of response of at least 6 months. Among 34 patients who had received both platinum-based chemotherapy and a HER2-targeted antibody-drug conjugate, the objective response and duration of response rates were 44% and 27%, respectively. Boehringer Ingelheim reported that dose reductions occurred in only 5% of patients, and only 2.9% discontinued treatment. Most treatment-related adverse events were manageable, with diarrhea, hepatotoxicity, and rash occurring most commonly. The prescribing information, which will be posted at Drugs@FDA, includes warnings and precautions for hepatotoxicity, left ventricular dysfunction, interstitial lung disease, and embryo-fetal toxicity. The recommended zongertinib dose is 120 mg given orally once daily for patients who weigh less than 90 kg and 180 mg given orally once daily for those who weigh 90 kg or greater. Zongertinib can be taken with or without food and can be continued until disease progression or unacceptable toxicity, according to the full prescribing information.
Yahoo
2 days ago
- Health
- Yahoo
U.S. FDA grants accelerated approval to Boehringer's HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
Illustrative image This press release is not intended for UK media. HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% (N=71), as demonstrated in the Beamion-LUNG 1 clinical trial1 Accelerated approval follows Priority Review and Breakthrough Therapy Designation granted by the U.S. FDA for the treatment of patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer Ridgefield, Conn. U.S. and Ingelheim, Germany - Boehringer Ingelheim's HERNEXEOS® (zongertinib tablets) has been approved by the U.S. Food and Drug Administration (FDA). The kinase inhibitor is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.1 This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.1 'With the approval of zongertinib, we have an effective, targeted, orally administered treatment option for patients with HER2 (ERBB2)-mutant non-small cell lung cancer in the U.S. that not only elicits a durable response but, importantly, has a manageable safety profile,' said Dr. John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, and coordinating investigator for the Beamion-LUNG 1 trial. 'In a patient population where there are currently limited treatment options, this approval represents a significant advancement in cancer care.' Accelerated approval is based on data from the Phase Ib Beamion-LUNG 1 trial, demonstrating an objective response rate of 75% (N=71), 6% of patients had a complete response and 69% of patients had a partial response and a duration of response of ≥6 months in 58% of patients (n=53).1 Positive results from the Beamion-LUNG 1 trial were previously presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 and simultaneously published in The New England Journal of Medicine.2 Zongertinib demonstrated a manageable safety profile with a 2.9% discontinuation rate. In the pooled safety population, the most common (> 20%) adverse reactions were diarrhea (53%), hepatotoxicity (27%), rash (27%), fatigue (22%), and nausea (21%).1 'We are grateful to be able to bring forward HERNEXEOS, which has the potential to reset the benchmark for those living with HER2-mutant advanced non-small cell lung cancer, a condition associated with a particularly poor prognosis,' said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. 'Believing in the power of scientific innovation, we aim to provide meaningful improvements to this patient population. Recognizing its potential, we accelerated development to deliver this new treatment option to patients within four years of starting the first clinical trial." Harnessing the power of precision medicine by targeting HER2 mutations in lung cancer HER2 (ERBB2) mutations occur in approximately 2–4% of NSCLC cases and are associated with a poor prognosis and higher incidence of brain metastases.3,4,5 Alterations in the HER2 (ERBB2) gene, including mutations, amplification and overexpression, trigger uncontrolled cell proliferation, inhibiting cell death, and promoting tumor growth and spread.3,5 Comprehensive biomarker testing using next generation sequencing determines a patient's eligibility for treatment with zongertinib by identifying HER2 (ERBB2)-mutant advanced NSCLC.1,5 'The advocacy community is thrilled about the approval of zongertinib, as it is another testament to the importance of personalized options for lung cancer that allow for a much more targeted approach for a subgroup of patients who have been waiting many years for innovative treatments,' said Marcia Horn, President and CEO, International Cancer Advocacy Network and Executive Director of the Exon 20 Group/HER2 Warriors. 'Understanding your cancer's unique biomarkers, including HER2, through comprehensive testing is critical for all patients with NSCLC, as it can unlock targeted treatment options.' About non-small cell lung cancer (NSCLC) Lung cancer claims more lives than any other cancer type and the incidence is set to increase to over 3 million cases worldwide by 2040.5,6 NSCLC is the most common type of lung cancer.3 Due to a lack of symptoms and misdiagnoses,7 most patients with NSCLC present at stage III or IV, where the disease has metastasized locally or to other organs.8 The estimated 5-year survival rate historically has been less than 10% for metastatic disease.9,10,11 People living with advanced NSCLC can experience a detrimental physical, psychological, and emotional impact on their daily lives.12,13,14 About zongertinib Zongertinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 (ERBB2).1 This orally administered, targeted therapy was approved as HERNEXEOS® (zongertinib tablets) under the FDA's Accelerated Approval Program, after securing Priority Review as well as Breakthrough Therapy and Fast Track Designations.1 The treatment is being evaluated in ongoing trials, across a range of advanced solid tumors with HER2 alterations. About Boehringer Ingelheim in oncology We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Boehringer Ingelheim's generational commitment to driving scientific innovation is reflected by the company's robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. Boehringer's ambition in oncology is to take a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations. Read more at and, About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at and The following information is intended for U.S. audiences only: About HERNEXEOS® HERNEXEOS® (zongertinib tablets) is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy. Boehringer Ingelheim's CareConnect4Me patient support program Boehringer's goal is to make HERNEXEOS® (zongertinib tablets) easily accessible in the U.S. through a comprehensive patient support program, CareConnect4MeTM, that provides a broad range of access and clinical support solutions, including financial support services. For those in the U.S., visit or call 1-855-297-5903 to learn more. What is HERNEXEOS (zongertinib tablets)? HERNEXEOS is a prescription medicine used to treat adults with a type of lung cancer called non-squamous non-small cell lung cancer (NSCLC) that: cannot be removed by surgery or that has spread to other parts of your body (metastatic), an has a certain mutation in the human epidermal growth factor receptor 2 (HER2) gene, and who have previously received treatment by mouth or injection (systemic therapy). Your healthcare provider will perform a test to make sure HERNEXEOS is right for you. It is not known if HERNEXEOS is safe and effective in children. IMPORTANT SAFETY INFORMATION Before taking HERNEXEOS, tell your healthcare provider about all of your medical conditions, including if you: have liver problems. have heart problems. have lung or breathing problems other than lung cancer. are pregnant or plan to become pregnant. HERNEXEOS can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider will do a pregnancy test before you start treatment with HERNEXEOS. Use an effective form of birth control (contraception) during treatment with HERNEXEOS and for 2 weeks after your last dose. Talk to your healthcare provider about birth control methods that might be right for you during this time. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with HERNEXEOS. are breastfeeding or plan to breastfeed. It is not known if HERNEXEOS passes into your breastmilk. Do not breastfeed during treatment and for 2 weeks after your last dose of HERNEXEOS. Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. HERNEXEOS may affect the way other medicines work, and other medicines may affect how HERNEXEOS works. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine. What are the possible side effects of HERNEXEOS? HERNEXEOS may cause serious side effects, including: liver problems. Liver problems are common with HERNEXEOS and can be severe and life threatening. Your healthcare provider will do blood tests to check your liver function before you start taking HERNEXEOS and during your treatment. Tell your healthcare provider right away if you develop any signs and symptoms of liver problems, including: yellowing of your skin or the white part of your eyes (jaundice) dark or brown (tea colored) urine pain on the upper right side of your stomach area (abdomen) bleeding or bruising more easily than normal feeling very tired loss of appetite nausea or vomiting heart problems that may affect your heart's ability to pump blood. HERNEXEOS can cause heart problems. Your healthcare provider will do tests to check your heart function before you start taking HERNEXEOS and during treatment. Tell your healthcare provider right away if you have any new or worsening symptoms of heart problems, including: feeling like your heart is pounding or racing Dizziness Tiredness feeling lightheaded shortness of breath loss of consciousness coughing swelling of your legs, ankles, or feet lung problems. HERNEXEOS can cause lung problems that are severe or life-threatening. Tell your healthcare provider right away if you have any new or worsening symptoms of lung problems, including trouble breathing, shortness of breath, cough, or fever. Your healthcare provider may temporarily stop, decrease your dose, or permanently stop treatment with HERNEXEOS if you have serious side effects. The most common side effects of HERNEXEOS include: diarrhea. HERNEXEOS can cause severe diarrhea. Tell your healthcare provider right away if you have diarrhea. liver problems Rash feeling tired nausea The most common severe abnormal blood tests include decreased white blood cell count, increased liver function tests, and decreased potassium levels. HERNEXEOS may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of HERNEXEOS. Call your doctor for medical advice about side effects. For more information, ask your healthcare provider or pharmacist. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. For U.S. Healthcare Professionals, please see full Prescribing Information. CL--100065 07.28.2025 References: 1HERNEXEOS Prescribing Information 2Heymach, J. et al. Zongertinib in previously treated HER2-mutant non-small cell lung cancer. N Engl J Med. 2025;01-13. 3Baraibar I, et al. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. Crit Rev Oncol Hematol. 2020;148:102906. 4Li, B.T. et al. Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer. N Engl J Med. 2022;386:241–51 5Zeng J, Ma W, Young RB, Li T. Targeting HER2 genomic alterations in non-small cell lung cancer. J Natl Cancer Cent. 2021 May 3;1(2):58-73. 6International Agency for Research on Cancer – World Health Organization. Rates of trachea, bronchus and lung cancer. Available at: (Accessed: January 2025). 7American Cancer Society. Lung Cancer Early Detection, Diagnosis, and Staging. Available at: (Accessed: January 2025). 8Casal-Mouriño, A. et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506-518. 9National Cancer Institute Surveillance, Epidemiology, and End Results (SEER). 5-Year Survival (Accessed July 2025). 10Belaroussi, Y. et al. Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting. Sci Rep. 2023.13, 9584. 11Simeone, J. C. et al. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world US setting. Fut. Oncol. Lond. Engl. 2019. 15(30), 3491–3502. 12Valentine, T. R. et al. Illness Perceptions and Psychological and Physical Symptoms in Newly Diagnosed Lung Cancer. Health Psychol. 2022 Jun; 41(6): 379–388. 13Andersen, B. L. et al. Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms. Lung Cancer. 2020 Jul;145:195-204. 14Presley, C. J. et al. Functional Disability Among Older Versus Younger Adults With Advanced Non–Small-Cell Lung Cancer. JCO Oncol Pract. 2021 May 3;17(6):e848–e858. Attachment Illustrative imageError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hindustan Times
4 days ago
- Health
- Hindustan Times
Oncologist explains different types of lung cancers and which 1 'tends to progress more rapidly than others'
Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for the highest mortality rates among both men and women, as per World Health Organisation. In an interview with HT Lifestyle, Dr Tanveer Majeed, consultant surgical oncologist, Wockhardt hospitals, Mumbai Central explained the most common types of lung cancer. Also read | Pulmonologist explains 6 surprising habits that can harm your lungs even if you don't smoke Dr Majeed explained that while knowing the types is necessary, being aware of symptoms is equally important.(Unsplash) What is lung cancer? He said, 'Although lung cancer is a heterogeneous group of different histological types of cancers, they are clubbed together as lung cancer, each having a different growth pattern, mode of spread, and treatment options. The two broad types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). They are named based on the appearance of the cancer cells when viewed under a microscope; each has its own distinct characteristics.' What is non-small cell lung cancer? Non-small cell lung cancer [NSCLC] is the most prevalent lung cancer, accounting for approximately 80–85 percent of all diagnoses, Dr Majeed said. It tends to grow and spread more slowly than small-cell cancer, he added. 'NSCLC has three subtypes – adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Although smoking is a common risk factor for these cancers, adenocarcinoma in women and squamous cell carcinomas, other factors like radon gas and asbestos exposure can also contribute to NSCLC. Large cell carcinoma, which may occur in any region of the lung, tends to progress more rapidly than other subtypes,' he explained. What is small cell lung cancer? According to Dr Majeed, small cell lung cancer represents approximately 10–15 percent of lung cancers. 'It has a definite link to smoking and is recognised for its rapid growth and rapid metastasis to the rest of the body, especially the adrenals and brain. This makes it more difficult to detect early and more difficult to treat, usually necessitating the use of multiple treatments such as chemotherapy and radiation,' he said. Other types of cancer 'Less frequent are other types of cancers occurring in the lung, for examples, neuroendocrine cancer [NEC] and bronchial carcinoids, of which carcinoids are slow to grow and are not generally associated with smoking. While unusual, these can be effectively treated if caught early,' Dr Majeed said. The doctor added that confirming the type of lung cancer is essential since it will literally determine the treatment and indicate the outcomes (overall and disease-free survival). 'With the advancements in the field of molecular biology, various molecular markers, and next-generation sequencing [NGS], novel therapies such as targeted therapy and immunotherapy have provided more tailored alternatives even in advanced stages of lung cancer,' he said. What else should you know? Dr Majeed explained that while knowing the types of lung cancer is necessary, being aware of symptoms is equally important: 'A persistent cough, chest pain, sudden weight loss, tiredness, or breathlessness should never be neglected. Detection at an early stage makes all the difference in how well the disease can be treated.' He added, 'Lung cancer is an aggressive disease which is treated differently based on various subtypes and presence of various markers. Awareness about the symptoms of lung cancer leads to early detection with a better outcome. Screening methods using low-dose CT scans of the thorax contribute significantly to outcomes.' Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Yahoo
5 days ago
- Business
- Yahoo
Lung Cancer Screening Market to Reach USD 7.44 Billion by 2032, Driven by LDCT Adoption and Growing High-Risk Population
Global Lung Cancer Screening Market Forecast (2025–2032) Shows 9.32% CAGR, U.S. Market to Hit USD 2.21 Billion by 2032 Amid Early Detection Demand and Technological Advancements. Austin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lung Cancer Screening Market Size & Growth Analysis: According to SNS Insider, The Lung Cancer Screening Market was estimated at USD 3.66 billion in 2024 and is expected to reach USD 7.44 billion by 2032, at a CAGR of 9.32% during the forecast period of 2025-2032. The global lung cancer screening market growth is driven by the increasing prevalence of lung cancer and growing adoption of screening, initiatives to increase awareness about lung cancer, and the introduction of new and advanced products. Favorable governmental policies, rising healthcare infrastructure, and technological advancements are other factors driving Free Sample Report of the Lung Cancer Screening Market: The U.S. lung cancer screening market was estimated at USD 1.12 billion in 2024 and is expected to reach USD 2.21 billion by 2032, at a CAGR of 8.89% during the forecast period of 2025-2032 The U.S. dominated the North American lung cancer screening market, driven by robust policy support and early uptake of low-dose computed tomography (LDCT) among the eligible high-risk population of 50 to 80-year-olds with a smoking history of 20+ pack-years under updated USPSTF guidelines. Segmentation & Regional Highlights By Modality, the LDCT Segment Dominates the Lung Cancer Screening Market in 2024 The low-dose computed tomography (LDCT) segment held the largest share of the lung cancer screening market in 2024 with a 61.2% market share owing to high accuracy, non-invasive nature, and support by such as the U.S. Preventive Services Task Force (USPSTF) and other major health societies. LDCT allows early lung cancer diagnosis in high-risk patients and dramatically improves survival. Incorporation of cancer screening and insurance coverage has facilitated adoption, particularly in the developed world. By Cancer Type, the Non-Small Cell Lung Cancer (NSCLC) Segment Dominates the Market and is Witnessing High Growth Over the Forecast Period Non-small cell lung cancer (NSCLC) segment held a major share of the lung cancer screening market in 2024 as a result of the high prevalence of NSCLC among the population, which accounts for nearly 85% of all lung cancer cases around the globe. NSCLC is slow compared to small cell lung cancer, making it possible for more cases to be found early and diagnosed during screening. The demand for NSCLC screening has also increased with the development of targeted therapies and biomarkers for NSCLC. The 60–69 Years Segment Dominated the Lung Cancer Screening Market by Age Group The 60–69 years age group dominated the Lung Cancer Screening Market in the year 2024, owing to the higher prevalence of lung cancer in this age group. Members of this group are usually longer-term smokers or have had more exposure to carcinogens, and are therefore at higher risk, justifying the need for regular screening. Many countries' medical guidelines give this age range priority for low-dose CT screening, which has driven an increase in use. Lung Cancer Screening Market in North America Led in 2024 with a 40.3% Market Share, APAC Poised to be the Fastest-Growing Regional Market. The lung cancer screening market in North America is driven by the well-developed healthcare system, early uptake of advanced screening technologies such as LDCT, and favorable reimbursement scenarios. Marked awareness of lung cancer, full-scale enforcement of national screening guidelines, and a strong position of key players provide additional prospects for regional supremacy. Screening programmes promoted by governmental institutions such as the U.S. Preventive Services Task Force (USPSTF) have increased the screening rates, especially in high-risk individuals, and the region has evolved into a global market leader. The Asia-Pacific lung cancer screening market is estimated to register the highest CAGR, on account of a rise in the incidence of lung cancer, increasing awareness, and the increasing healthcare expenditure in the region. China, India, Japan, and other countries are enhancing early cancer screening initiatives, expanding access to LDCT and biomarker testing. For a Personalized Briefing with Our Industry Analysts, Connect Now: Key Lung Cancer Screening Companies Profiled in the Report GE HealthCare Siemens Healthineers Philips Healthcare Canon Medical Systems Corporation Fujifilm Holdings Corporation Samsung Medison Co. Ltd. Carestream Health Shimadzu Corporation Vuno Inc. Zebra Medical Vision Aidoc Riverain Technologies Lunit Inc. Roche Diagnostics Illumina Inc. Guardant Health Exact Sciences Corporation Bio-Rad Laboratories CT Screening International and other players. Lung Cancer Screening Market Report Scope Report Attributes Details Market Size in 2024 US$ 3.66 billion Market Size by 2032 US$ 7.44 billion CAGR CAGR of 9.32% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Key Growth Drivers Growing incidence of lung cancer worldwide Increased public awareness and government-led screening programs Advancements in imaging technologies (e.g., AI-enabled CT scans) Rising demand for non-invasive and early-stage cancer detection Supportive reimbursement policies in the U.S. and Europe Unique Selling Propositions (USPs) of the Report: Country-level eligibility for the screening landscape Assists your company in prioritizing markets that have high potential opportunity by comparing age, risk, and reimbursement criteria for screening across countries. Adoption curves comparison: LDCT vs. new technologies Facilitates strategic planning by identifying lung cancer screening early adopters vs. laggards for LDCT and next-gen technologies, and helps to launch market entry timing. Biomarker Inclusion in Lung Screening Helps companies make R&D and partnership decisions by monitoring how molecular diagnostics are supplementing or undercutting traditional screening. RoS (Return on Screening) Modelling Measures the cost per site of value of your screening programs to enable XYZ Company to create a persuasive business case for customers or reimbursement agencies, or health authorities. Buy the Full Lung Cancer Screening Market Report (Single-User License) Now: About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
&w=3840&q=100)
First Post
7 days ago
- Health
- First Post
Ditch that soda and noodles. The lung cancer link to ultra-processed foods
A study in the Thorax journal reveals that those consuming ultra-processed foods like fast food and sugary drinks have a 41 per cent higher risk of developing lung cancer compared to those who ate the least. The study analysed data of over 100,000 Americans aged 55 to 74, who were tracked for more than a decade read more We've known for a while that our go-to ultra-processed foods, like fast food, sugary drinks, and instant meals, aren't exactly the best for our health. They're often linked to heart problems and metabolic issues. But now, a new study points to another worrying connection. These foods might also raise the risk of lung cancer. Published in the journal Thorax, the research found that people who ate the most ultra-processed foods had a 41 per cent higher risk of developing lung cancer compared to those who ate the least. STORY CONTINUES BELOW THIS AD So, what counts as ultra-processed food? And how could it be linked to cancer? Here's what we know about the new study. But first, what are ultra-processed foods? Ultra-processed foods (UPFs) are industrially manufactured products made from a combination of refined ingredients and additives. They are designed to be hyper-palatable, convenient, and have a long shelf life. Unlike minimally processed foods, UPFs are made mostly from substances extracted from foods, such as fats, starches, added sugars, and unhealthy fats, rather than the whole food itself. They undergo extensive alterations and typically contain artificial substances like emulsifiers, preservatives, colourants, and sweeteners. As a result, UPFs tend to be calorie-dense but low in essential nutrients and fibre, making them nutritionally poor despite their appealing taste. Rows of ultraprocessed potato chips are placed at a convenience store in Boston. File image/AP In the UK and US, more than half of the average diet consists of ultra-processed foods (UPFs), which include frozen meals, soft drinks, hot dogs and cold cuts, fast food, packaged cookies, cakes, and salty snacks. What does the new study reveal? The study draws data from the US Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, which followed over 100,000 Americans aged 55 to 74. Participants enrolled between 1993 and 2001, and their health was tracked for more than a decade. Out of 101,732 people who filled out food questionnaires at the start, researchers categorised their diets based on how processed the foods were, with a special focus on ultra-processed foods (UPFs) like lunch meats, soft drinks, ice cream, baked goods, instant noodles, and fast food. Researchers believe rising global consumption of UPFs could be contributing to the growing burden of diseases, such as cancer. Image for Representation. Reuters On average, people consumed nearly three servings of UPFs a day, with some having up to six. Over 12 years, 1,706 lung cancer cases were diagnosed, including both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). STORY CONTINUES BELOW THIS AD Even after accounting for factors like smoking and diet quality, those who ate the most UPFs had a 37 per cent higher risk of NSCLC and a 44 per cent higher risk of SCLC. The researchers believe rising global consumption of UPFs could be contributing to the growing burden of diseases, such as cancer and stressed the need for more research to confirm these findings across diverse populations. 'Over the past two decades, consumption of ultra-processed foods has significantly increased worldwide, regardless of development or economic status,' the authors wrote. This rise may be driving global increases in obesity, cardiovascular disease, and cancer, they added. How might heavily processed foods increase cancer risk? Researchers believe one reason is that ultra-processed foods often replace healthier options, like fruits, vegetables, and whole grains, that may help protect against cancer. When diets become dominated by UPFs, there's simply less room for the good stuff. There's also growing concern about the additives and chemicals found in these products. Ingredients like emulsifiers, preservatives, artificial colours, and acrolein (a toxic compound also found in tobacco smoke) may lead to inflammation, disrupt hormones, damage DNA, and upset the gut microbiome. The packaging materials used for many of these foods can also be a source of risk. Chemicals like bisphenol A (BPA) and phthalates, commonly found in food containers and wrappers, may leach into the food and have been linked to health issues, the study noted. STORY CONTINUES BELOW THIS AD So, what can you do? Nutritionist Rob Hobson, author of Unprocess Your Family Life, told The Independent that it's less about blaming specific foods and more about c 'That might mean cooking more from scratch where possible, adding in more whole foods like vegetables, beans and grains, or just becoming more aware of how often UPFs show up in your day,' he said Also read: What is fibremaxxing, the new diet trend taking over social media? How safe is it? Making small, sustainable changes will help you gradually replace junk food with more nutritious, whole foods Image for Representation. Pixabay 'It's not about being perfect, it's about balance and understanding how your food choices could be supporting or undermining your long-term health.' In short, cutting back on ultra-processed foods doesn't require a complete lifestyle overhaul. But being mindful of how often these foods appear on your plate, and gradually replacing them with more nutritious, whole foods, can go a long way in supporting better health. With input from agencies
